Key result
Potential drug-drug interactions affect ~55% of hypertensive pregnant women and correlate with prescribed medication count.
Why the study?
The frequency and clinical relevance of potential drug-drug interactions among hypertensive pregnant women were not well characterized.
What is the prevalence of potential drug-drug interactions among hypertensive pregnant women?
Cross-Sectional (n=127)
No
What is the prevalence of potential drug-drug interactions among hypertensive pregnant women?
Over half of hypertensive pregnant women admitted to a tertiary care hospital experienced potential drug-drug interactions, highlighting the need for careful prescription monitoring.
Potential interactions with polypharmacy in hypertensive pregnancies merit vigilance; hypothesis-generating and should not yet change practice.
AIMS AND OBJECTIVES: The aim is to determine the frequency of potential drug-drug interactions (pDDIs) and to analyze the clinically relevant drug interactions among hypertensive pregnant women. MATERIALS AND METHODS: This was an observational, cross-sectional study conducted at a tertiary care hospital. The prescriptions of the hypertensive pregnant women admitted to the hospital from June 2021 to December 2021 were analyzed for potential drug-drug interactions using the database from Lexicomp ® Solutions android mobile application version 7.5.4 (Wolters Kluwer, The Netherlands). RESULTS: A total of 127 patients were evaluated during the study period of 6 months, of which 70 (55.12%) had pDDIs. The total number of pDDIs was 85, of which 70 (82.35 %) were clinically relevant interactions with the majority of them having moderate severity (81.17%) followed by minor severity (17.65%) and major severity (1.18%). The most frequently interacting pDDIs were between Labetalol and Lornoxicam (42.35%), followed by Labetalol and Diclofenac (22.35%). CONCLUSION: This study highlights the high prevalence of potential drug interactions among hypertensive pregnant women and the need for rational drug use and strict vigilance in their monitoring.
No takes yet. Share an insight, caveat, or question.
Ragam et al. (2023) conducted a cross-sectional in Hypertension in pregnancy (n=127). Prescribed medications was evaluated on Prevalence of potential drug-drug interactions (pDDIs). Among 127 hypertensive pregnant women, 55.12% experienced potential drug-drug interactions, which significantly correlated with the number of prescribed medications (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: